AC Immune/Roche Drop Crenezumab After Phase III CREAD Alzheimer's Failure
Interim top-line data from CREAD 1 and 2 indicate crenezeumab is unlikely to meet its primary endpoints and the studies are being stopped, but a clinical study in Colombia in familial Alzheimer’s is set to continue.
You may also be interested in...
Deal Snapshot: Roche is finally returning the rights to two failed Alzheimer’s candidates. But why now?
UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.
As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.